Currently, she is doing a postdoc at Tufts University with Dr. Michael Levin at the Allen Discovery Center. Also she is working to understand novel bioelectric controls of cell-cell interactions. Specifically, ion channel modulation of glioblastoma and stem cell differentiation. Her other projects have involved altering cellular resting membrane potentials to control the innervation of murine muscle cells grown in 2D and in ex vivo explants. She also work on methods for investigating primary cellular cognition.

Yuri Deigin, MBA is a biotech entrepreneur with a focus on early-stage translation of scientific breakthroughs into therapies. He has over a decade of drug discovery and development experience, and a track record of outlicensing products to Big Pharma.

Currently, she is using neuroimaging, fluid biomarkers and neuropsychological testing to define between different subtypes of disease, with an ultimate aim to improve treatments. Maryna is also interested in Personalized solutions that predict treatment efficiency in depression and progression of neurodegenerative diseases. Beside this she is currently teaching introduction to medicine with a focus on digital health in HTW Berlin and giving lectures on basics of nervous activity, depression and schizophrenia at the University of Leipzig and Max Planck.

Medical doctor and Ph.D. student interested in Molecular medicine, Bioinformatics, Machine learning, and Anti-aging research.

Nikola is a bioinformatician at the Buck Institute for Research on Aging. He is interested in the mechanisms of aging with special emphasis on brain aging. He applies multi-omics systems approaches to untangle the process of normal and pathological aging.

Alexander Fedintsev is a scientist and machine learning engineer. His scientific background lies in the field of bioinformatics, statistics, and machine learning. Alexander earned his M.S. in computer science from the National Research University “Moscow Power EngineeringInstitute”. Alexander worked in the Institute of Antimicrobial Chemotherapy as a bioinformatician. He also collaborated with professor Alexey Moskalev’s lab on aging research. After quitting academia, Alexander switched to machine learning engineering however he continued collaborating on aging research with professor Moskalev. He developed a highly accurate non-invasive biomarker of aging based on markers of the cardiovascular system. Now his research interest is mainly focused on the role of extracellular matrix (ECM) in the aging process. He and professor Moskalev recently suggested treating non-enzymatic modifications of long-living proteins (mostly, in the ECM) as a 10th hallmark of aging.

Machiavelli is a biohacker and gene therapy activist developing gene therapy for the masses.

Dr Nora Khaldi is an award-winning TEDx speaker and a highly published mathematician and scientist. Nora’s revolutionary and innovative ideas and inventions have been awarded and recognised by the likes of Forbes, Wired and the EU Commission. After leaving her academic career in early 2014, Nora decided to focus exclusively on disrupting the way therapeutic molecules were being discovered. She thus created Nuritas™, the first company in the world to introduce artificial intelligence (AI) to the food arena with the aim of creating the future of food and personalised nutrition, in a nutshell, the future of health. Based in Dublin, Ireland, Nuritas™ is revolutionising health and food systems through the accelerated discovery of therapeutic health-benefiting molecules from food.

Zvonimir Vrselja received his M.D. and Ph.D. from J. J. Strossmayer University in Croatia. After completing his graduate education, he started his postdoctoral training at Yale University in the United States of America. He currently holds the position of Associate Research Scientist in the Sestan Laboratory at the Yale School of Medicine. His research focuses on the development of a system that preserves global anatomical organization, as well as cellular organization, attenuates cell death, and restores neuronal, glial, and vascular functionality, along with global metabolism, in isolated large mammalian brains several hours after death.

Postdoctoral Fellow at Harvard T.H. Chan School of Public Health

Dr Delphine Larrieu completed her PhD in 2010 at the University of Grenoble, France. She then undertook her postdoctoral training with Professor Steve Jackson at the University of Cambridge, with independent funding from EMBO and from the Medical Research Council. She then obtained a Sir Henry Dale Wellcome Trust fellowship, allowing her to set up her own lab at the Cambridge Institute for Medical Research. Delphine’s lab is interested in understanding mechanisms driving rare premature ageing syndromes called progeria, and in identifying new ways to treat these diseases.

Iosif M. Gershteyn is a serial entrepreneur with a track record of founding companies in the biologics and medical device industries. Upon completing his graduate studies in international economics and finance at Brandeis University in 2009, he started his career in asset management working on long-term qualitative investment strategies. Subsequently, he worked in corporate strategy (including mergers and acquisitions) and ultimately embarked on a career in technology entrepreneurship. Alongside his primary occupation, he pursued interests in biology (neuroscience, immunology and physiology) after the completion of his formal education. These interests led him to found the Immunodietica project, which generates published research in the fields of immunology and computational systems biology. Since 2016, he has chaired the Ajax Biomedical Foundation and believes that computational systems have underexplored promise in multiple applications of human health, finance, and complex systems analysis. He is currently CEO of ImmuVia, an oncology therapeutics company.

Since you ‘cannot change what you cannot measure’, Brad endeavors to bring accessible, affordable, and scientifically sound aging biomarkers to the general public. As a researcher, Brad investigates these age-associated changes — epigenetic methylation marks — looking for why they accompany such profound, unprecedented consequences, in both naturally aged tissue and reprogrammed cells.

Before getting her hands dirty in the messy world of biology, Tatyana was pursuing her dream of becoming an astronaut. After completing her degree in electrical engineering, she worked as a signal processing engineer at NASA’s Jet Propulsion Laboratory (JPL). Tatyana volunteered her nights and weekends doing research at Caltech in neuroprosthetics and viral engineering to get a grasp on how engineering is used to probe and fix biology at its core – the cell. She then pursued her passion full time and got a PhD from Caltech where she got a chance to work on cell engineering, adeno-associated viruses, and single-cell RNA sequencing. Tatyana is now a CEO and a Co-Founder of ImYoo Inc. which is working on using single-cell immune profiling to connect people with similar immune profiles to share their health journeys.

Nikolina Lauc is a successful serial entrepreneur with 11 years of experience. She co-founded several startups in the field of fashion, SaaS, travel and biotech, scaling them from one customer to a 3M+ in revenue with no investor backing. She has extended experience in optimising resources, managing small teams in fast-growth environments and building consumer products and services that focus on retention. As an outsider to biotech, she’s already uncovered a novel application for an existing technology that was missed by 50+ scientists in its research lab. She’s the co-inventor of a patent in the women’s health diagnostics space. As Chief Executive Officer, she will be leading GlycanAge in its development from a biomarker in research to a consumer product.

Kai Micah Mills is a serial entrepreneur with over a decade of experience building and scaling tech companies, most recently Branch Technologies. His focus is now in the cryonics field with his new company Cryopets, constructing an animal hospital and cryonics facility hybrid to advance the science of full-body cryopreservation for pets and humans alike.

Matthew McAteer is a researcher, engineer, and entrepreneur with years of experience in biotech. Matthew has worked in labs addressing age-related diseases at Brown University, MIT, and Mass General Hospital. This was followed by working on using symbolic regression to design cheaper NAD+ precursor production systems. After working with Google’s Tensorflow team on probabilistic programming toolkits, Matthew began building ML pipelines for various biometric authentication and drug discovery startups. He is currently working on ways to make adopting private machine learning best practices easier to adopt for both industry and academia.